Y-27632

Blockade of integrin β3 suppresses the tumor growth and relives the drug resistance in melanoma. a Quantification of colonies formed by the β3+ population from A375 cells treated with PBS and cilengitide (10 nM). b Tumorigenicity of the β3+ population from A375 cells pre-treated with PBS and cilengitide (10 nM) for 24 h. C Cell viability of sorted β3+ A375 cells treated with DOX (1 µg/mL), DOX (1 µg/mL) combined with cilengitide (10 nM), MTX (0.5 µg/mL) and MTX (0.5 µg/mL) combined with cilengitide (10 nM) for 24 h. d Tumor volume of mice subcutaneously injected with 2 × 106 A375 cells treated with PBS, cilengitide, DOX and DOX combined with cilengitide. e Survival rate of mice subcutaneously injected with 2 × 106 A375 cells treated with PBS, cilengitide, DOX and DOX combined with cilengitide. f Tumor volume of mice subcutaneously injected with 2 × 106 sorted β3+ A375 cells treated with PBS, cilen-gitide, DOX and DOX combined with cilengitide. g Survival rate of mice subcutaneously injected with 2 × 106 sorted β3+ A375 cells treated with PBS, cilengitide, DOX and DOX combined with cilen- gitide. The data was presented as the means ± SEM from three inde-pendent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ns not statistically significant